Archive
America Has a New Sunscreen Filter: What Bemotrizinol Really Changes
The first U.S. sunscreen using newly permitted BEMT has arrived. LCY separates the regulatory breakthrough, formulation science and marketing hype.
Category
Archive
116 stories · page 8 of 10
Science
Senotherapeutic Skincare: What the OS-01 Pilot Can—and Cannot—Show
A careful reading of the small company-linked OS-01 formula trial, including its multi-active design, skin reactions, conflicts of interest and need for independent replication.
Trends
K-Beauty Medicosmetics: A Retail Signal That Still Needs Ingredient-Level Proof
PDRN, exosomes and peptides may share retail momentum, but they are not one efficacy class; identity, route, dose and finished-product evidence remain decisive.
Trends
Skin Longevity: New Biology, Useful Framework—or Anti-Aging Rebrand?
Biology and biomarkers can guide research, but extending “skin longevity” is not yet a standardized clinical outcome or a blanket cosmetic claim.
Trends
Climate-Adaptive Beauty: Barrier Physiology Does Not Validate a Product Label
Temperature, humidity and pollution can influence skin measurements, but heterogeneous environmental evidence does not prove that a “climate-adaptive” cosmetic works.
Trends
Hair Longevity Is a Framework—Not Yet a Proven Product Category
A European expert consensus can organize research questions, but it is not product-outcome evidence or proof of a global market trend.
Trends
Post-GLP-1 Aesthetics: A Survey Signal, Not a Proven Market Shift
A survey-led trend signal on post-weight-loss skin concerns, separated from clinical evidence for skin change and from claims that any aesthetic treatment is effective.
Aesthetics
GLP-1 Medicines and Hair Loss: What the Association Signal Shows
Large reviews and current labeling support an association signal, but they do not prove one direct mechanism for every case or justify stopping treatment without a prescriber.
Aesthetics
At-Home LED Masks: Where the Evidence Is Strongest—and Where Marketing Runs Ahead
At-home LED evidence is indication-, device- and protocol-specific: selected acne studies do not validate every rejuvenation claim.
Science
A 0.002% Peptide Outperformed 0.002% Retinol in One Company-Authored Trial
A precise comparison of cyclized hexapeptide-9 and a very low-dose retinol comparator—without turning one 56-day company-authored study into a class-wide verdict.
Aesthetics
Injectable Exosomes: Why the Safety Conversation Is Different
Topical and injectable exosome claims should never be treated as the same evidence category.
Science
Vegan PDRN: Innovation Claim or Naming Shortcut?
Why plant- or biotech-derived nucleotide materials need analytical equivalence and product-specific human evidence before inheriting clinical PDRN claims.